A Phase 3 interventional study of Sodium Zirconium Cyclosilicate (ZS) 10g and Sodium Zirconium Cyclosilicate (ZS) 5g in Hyperkalemia, sponsored by AstraZeneca. Completed at 45 sites in 4 countries. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2020-08-19.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies testing sodium zirconium cyclosilicate in Hyperkalemia — 3 open to participants now, 4 under way, none of them phase 3. sodium zirconium cyclosilicate · Hyperkalemia.
Among the 27 studies testing sodium zirconium cyclosilicate in Hyperkalemia, this one is the 6th largest by enrollment, is one of 4 that started in 2017, is one of 12 in phase 3, and was the 4th registered.
134 studies on the registry are indexed under Hyperkalemia; 26 are open to participants now.
Browse Hyperkalemia studies →3 of the 27 studies testing sodium zirconium cyclosilicate in Hyperkalemia are open now, in 2 countries. Recruiting first, the newest first:
AstraZeneca · Sites in India
Ages 18+
Leiden University Medical Center · Sites in Netherlands
Ages 18+
Qianfoshan Hospital
Ages 18–75
By country, each count listing its studies:
sodium zirconium cyclosilicate: first FDA approval 2018 (LOKELMA), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 16 Hyperkalemia studies recruiting now, 11 (69%) set no upper age limit and 2 (13%) stop at 75 or younger; 2 take children under 18; none take healthy volunteers.
This study: 18 Years to 90 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 5 · Phase 3 13 · Phase 4 6
First in 2014; this study’s year is marked. 4 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 267 is above the median of 88 across 103 interventional studies indexed under Hyperkalemia.
Median enrollment 120 across the 27 interventional studies. Of the 22 that completed or were terminated, 18 (82%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 27 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,505 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
39 studies in Hyperkalemia by AstraZeneca: 2 open now, 3 under way, 1 of them phase 3. Of 36 finished, 22 (61%) have results posted.
Among the 39 studies in Hyperkalemia by AstraZeneca, this one is the 8th largest by enrollment of the 25 interventional ones that give a count, is one of 6 that started in 2017, is one of 13 in phase 3, and was the 9th registered.
AstraZeneca’s Hyperkalemia studies by the year they started, since 2011.
2 of the studies testing sodium zirconium cyclosilicate in Hyperkalemia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06736184Qianfoshan HospitalThe Cardioprotective Effects of Improving Potassium Variability in Maintenance Hemodialysis Patients | 2026-12-31 |
| NCT07944378AstraZenecaA Study Evaluating the Safety and Effectiveness of Lokelma in Indian Patients With Hyperkalaemia | 2027-10-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 27 studies testing sodium zirconium cyclosilicate in Hyperkalemia, from their registry updates:
Among AstraZeneca’s 39 in Hyperkalemia:
This tab as a report to print or save as PDF → With an account.
To evaluate the efficacy of two different doses (5 and 10 g) of ZS orally administered once daily (qd) vs placebo in maintaining normokalemia in initially hyperkalemic patients having achieved normokalemia following two days of initial ZS therapy (10g TID).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Suspension administered 5g orally once daily for 28 days after the first 48-hour open label initial phase.
Drug: Sodium Zirconium Cyclosilicate (ZS) 5g
Suspension administered 10g orally once daily for 28 days after the first 48-hour open label initial phase.
Drug: Sodium Zirconium Cyclosilicate (ZS) 10g
Suspension administered orally placebo once daily for 28 days after the first 48-hour open label initial phase.
Drug: Placebo
Suspension administered 10g orally three times per day, in the first 48-hour of the study for all patients (48-hour open label initial phase)
Suspension administered 5g orally once daily for 28 days after the first 48-hour open label initial phase.
Suspension administered 10g orally once daily for 28 days after the first 48-hour open label initial phase.
Suspension administered orally placebo once daily for 28 days after the first 48-hour open label initial phase.
Least Square Mean S-K Level on Days 8-29
Comparison between placebo and the active ZS treatment groups (each dose group will be sequentially compared with placebo, starting with the highest and ending with the lowest dose) with regard to the mean S-K level during the 28-day randomized treatment study phase Days 8-29. The results in the table below are presented for RTP.
Time frame: Through 28-day randomized treatment study phase day 8-29.
Proportion of Patients Achieving Normokalemia
Proportion of patients who achieve normokalemia during the initial phase at 24 and 48 hours. The results in the table below are presented for OLP. (h=hours).
Time frame: Through 48-hour initial phase.
Exponential Rate of Change in S-K Levels
Exponential rate of change in S-K levels (blood) during the 48-hour open-label initial phase. The results in the table below are presented for OLP.
Time frame: Through 48-hour initial phase.
Absolute Change From Baseline in S-K Levels
Absolute change from baseline in S-K levels at all measured time intervals. The results in the table below are presented for OLP.
Time frame: Through 48-hour initial phase.
Percentage Change From Baseline in S-K Levels
Percentage change from baseline in S-K levels at all measured time intervals. The results in the table below are presented for OLP.
Time frame: Through 48-hour initial phase.
Proportion of Patients Remaining Normokalemic
The proportion of patients who remain normokalemic (as defined by S-K between 3.5-5.0 mmol/l, inclusive) at the end of the 28-day randomized treatment study phase and during the 28-day randomized treatment study phase. The results in the table below are presented for RTP.
Time frame: Through 28-day randomized treatment study phase day 8-29.
Proportion of Normokalemic Patients at Day 1 Through Day 29/Exit
The proportion of patients who are normokalemic (as defined by S-K between 3.5-5.0 mmol/l, inclusive) at Day 1 through Day 29/Exit in randomization phase. The results in the table below are presented for RTP.
Time frame: Through 28-day randomized treatment phase.
Days Patients Remain Normokalemic
The number of days patients remain normokalemic during the 28-day randomized treatment study phase. The results in the table below are presented for RTP.
Time frame: Through 28-day randomized treatment phase.
Mean Change in S-K Levels
The mean change in S-K levels evaluated relative to both baselines. The results in the table below are presented for RTP.
Time frame: Through 28-day randomized treatment phase.
Mean Percentage Change in S-K Levels
The mean percentage change in S-K levels evaluated relative to both baselines. The results in the table below are presented for RTP.
Time frame: Through 28-day randomized treatment phase.
Number of Hyperkalemic Patients
The results represent number of hyperkalemic patients during the 28-day randomized treatment study phase. The results in the table below are presented for RTP.
Time frame: Through 28-day randomized treatment phase.
Mean Changes in S-Aldosterone and P Renin Levels
The mean changes from OLP baseline in S-Aldosterone and P-Renin levels. The results in the table below are presented for RTP.
Time frame: Through 28-day randomized treatment phase.
Patient Reported Health State (EQ-5D) Questionnaire
Evaluate health state of patients using EQ-5D questionnaire. This scale is numbered from 0 to 100. 0 means the worst health you can imagine. 100 means the best health you can imagine. The results in the table below are presented for RTP.
Time frame: Through study completion, an average of 37 days.
This study was conducted in 42 centers within Japan, Russia, South Korea, and Taiwan.
| Milestone | Sodium Zirconium Cyclosilicate (ZS) 10g Tid | Sodium Zirconium Cyclosilicate (ZS) 5g | Sodium Zirconium Cyclosilicate (ZS) 10g | Placebo |
|---|---|---|---|---|
| Started | 267 | 0 | 0 | 0 |
| Completed | 260 | 0 | 0 | 0 |
| Not completed | 7 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 3 | 0 | 0 | 0 |
| Withdrew: (not collected) | 4 | 0 | 0 | 0 |
| Milestone | Sodium Zirconium Cyclosilicate (ZS) 10g Tid | Sodium Zirconium Cyclosilicate (ZS) 5g | Sodium Zirconium Cyclosilicate (ZS) 10g | Placebo |
|---|---|---|---|---|
| Started | 0 | 99 | 99 | 50 |
| Completed | 0 | 85 | 88 | 41 |
| Not completed | 0 | 14 | 11 | 9 |
| Withdrew: Withdrawal by subject | 0 | 3 | 1 | 0 |
| Withdrew: Protocol violation | 0 | 2 | 0 | 0 |
| Withdrew: (not collected) | 0 | 9 | 10 | 9 |
Comparison between placebo and the active ZS treatment groups (each dose group will be sequentially compared with placebo, starting with the highest and ending with the lowest dose) with regard to the mean S-K level during the 28-day randomized treatment study phase Days 8-29. The results in the table below are presented for RTP.
| mmol/L | Sodium Zirconium Cyclosilicate (ZS) 10g Tid | Sodium Zirconium Cyclosilicate (ZS) 5g | Sodium Zirconium Cyclosilicate (ZS) 10g | Placebo |
|---|---|---|---|---|
| Least Square Mean S-K Level on Days 8-29 | — | 4.811 (4.685 to 4.940) | 4.381 (4.265 to 4.501) | 5.321 (5.155 to 5.493) |
Proportion of patients who achieve normokalemia during the initial phase at 24 and 48 hours. The results in the table below are presented for OLP. (h=hours).
| Participants | Sodium Zirconium Cyclosilicate (ZS) 10g Tid | Sodium Zirconium Cyclosilicate (ZS) 5g | Sodium Zirconium Cyclosilicate (ZS) 10g | Placebo |
|---|---|---|---|---|
| Normokalemic at 24h | 169 | — | — | — |
| Not Normokalemic at 24h | 93 | — | — | — |
| Missing at 24h | 5 | — | — | — |
| Normokalemic at 48h | 238 | — | — | — |
| Not Normokalemic at 48h | 22 | — | — | — |
| Missing at 48h | 7 | — | — | — |
Exponential rate of change in S-K levels (blood) during the 48-hour open-label initial phase. The results in the table below are presented for OLP.
| log(mmol/L)/h | Sodium Zirconium Cyclosilicate (ZS) 10g Tid | Sodium Zirconium Cyclosilicate (ZS) 5g | Sodium Zirconium Cyclosilicate (ZS) 10g | Placebo |
|---|---|---|---|---|
| Exponential Rate of Change in S-K Levels | -0.004 ± 0.0001 | — | — | — |
Absolute change from baseline in S-K levels at all measured time intervals. The results in the table below are presented for OLP.
| mmol/L | Sodium Zirconium Cyclosilicate (ZS) 10g Tid | Sodium Zirconium Cyclosilicate (ZS) 5g | Sodium Zirconium Cyclosilicate (ZS) 10g | Placebo |
|---|---|---|---|---|
| OLP Day 1-1h post-first dose absolute change | -0.19 ± 0.444 | — | — | — |
| OLP Day 1-2h post-first dose absolute change | -0.48 ± 0.452 | — | — | — |
| OLP Day 1-4h post-first dose absolute change | -0.57 ± 0.494 | — | — | — |
| OLP Day 2-24h absolute change | -0.81 ± 0.398 | — | — | — |
| OLP Day 2-1h post-first dose absolute change | -0.91 ± 0.445 | — | — | — |
| OLP Day 3-48h absolute change | -1.28 ± 0.499 | — | — | — |
Percentage change from baseline in S-K levels at all measured time intervals. The results in the table below are presented for OLP.
| Percentage change | Sodium Zirconium Cyclosilicate (ZS) 10g Tid | Sodium Zirconium Cyclosilicate (ZS) 5g | Sodium Zirconium Cyclosilicate (ZS) 10g | Placebo |
|---|---|---|---|---|
| OLP Day 1-1h post-first dose percentage change | -3.26 ± 7.949 | — | — | — |
| OLP Day 1-2h post-first dose percentage change | -8.29 ± 7.792 | — | — | — |
| OLP Day 1-4h post-first dose percentage change | -9.88 ± 8.494 | — | — | — |
| OLP Day 2-24h percentage change | -14.08 ± 6.479 | — | — | — |
| OLP Day 2-1h post-first dose percentage change | -15.84 ± 7.243 | — | — | — |
| OLP Day 3-48h percentage change | -22.16 ± 7.812 | — | — | — |
The proportion of patients who remain normokalemic (as defined by S-K between 3.5-5.0 mmol/l, inclusive) at the end of the 28-day randomized treatment study phase and during the 28-day randomized treatment study phase. The results in the table below are presented for RTP.
| Participants | Sodium Zirconium Cyclosilicate (ZS) 10g Tid | Sodium Zirconium Cyclosilicate (ZS) 5g | Sodium Zirconium Cyclosilicate (ZS) 10g | Placebo |
|---|---|---|---|---|
| Proportion of Patients Remaining Normokalemic | — | 58 | 75 | 12 |
The proportion of patients who are normokalemic (as defined by S-K between 3.5-5.0 mmol/l, inclusive) at Day 1 through Day 29/Exit in randomization phase. The results in the table below are presented for RTP.
| Participants | Sodium Zirconium Cyclosilicate (ZS) 10g Tid | Sodium Zirconium Cyclosilicate (ZS) 5g | Sodium Zirconium Cyclosilicate (ZS) 10g | Placebo |
|---|---|---|---|---|
| Day 1 | — | 93 | 94 | 45 |
| Day 2 | — | 89 | 93 | 40 |
| Day 5 | — | 71 | 89 | 27 |
| Day 8 | — | 62 | 81 | 16 |
| Day 12 | — | 62 | 78 | 12 |
| Day 15 | — | 57 | 77 | 12 |
| Day 19 | — | 55 | 76 | 11 |
| Day 22 | — | 54 | 73 | 11 |
| Day 26 | — | 56 | 74 | 8 |
| Day 29 | — | 51 | 71 | 11 |
| Day 29/Exit | — | 58 | 77 | 12 |
The number of days patients remain normokalemic during the 28-day randomized treatment study phase. The results in the table below are presented for RTP.
| Day | Sodium Zirconium Cyclosilicate (ZS) 10g Tid | Sodium Zirconium Cyclosilicate (ZS) 5g | Sodium Zirconium Cyclosilicate (ZS) 10g | Placebo |
|---|---|---|---|---|
| Days Patients Remain Normokalemic | — | 10.810 ± 1.113 | 15.623 ± 1.143 | 3.543 ± 1.351 |
The mean change in S-K levels evaluated relative to both baselines. The results in the table below are presented for RTP.
| mmol/L | Sodium Zirconium Cyclosilicate (ZS) 10g Tid | Sodium Zirconium Cyclosilicate (ZS) 5g | Sodium Zirconium Cyclosilicate (ZS) 10g | Placebo |
|---|---|---|---|---|
| Day 2 change from RTP baseline | — | 0.03 ± 0.354 | -0.09 ± 0.372 | 0.17 ± 0.443 |
| Day 5 change from RTP baseline | — | 0.23 ± 0.478 | -0.08 ± 0.439 | 0.60 ± 0.562 |
| Day 8 change from RTP baseline | — | 0.44 ± 0.487 | 0.00 ± 0.489 | 0.91 ± 0.622 |
| Day 12 change from RTP baseline | — | 0.53 ± 0.560 | 0.05 ± 0.573 | 0.97 ± 0.646 |
| Day 15 change from RTP baseline | — | 0.54 ± 0.584 | 0.04 ± 0.564 | 0.85 ± 0.585 |
| Day 19 change from RTP baseline | — | 0.56 ± 0.578 | 0.05 ± 0.576 | 0.97 ± 0.566 |
| Day 22 change from RTP baseline | — | 0.47 ± 0.555 | 0.10 ± 0.613 | 0.93 ± 0.702 |
| Day 26 change from RTP baseline | — | 0.51 ± 0.581 | 0.05 ± 0.639 | 1.01 ± 0.607 |
| Day 29 change from RTP baseline | — | 0.47 ± 0.586 | 0.02 ± 0.665 | 1.02 ± 0.594 |
| EOS change from RTP baseline | — | 0.92 ± 0.661 | 0.77 ± 0.695 | 0.88 ± 0.684 |
| Day 2 change from OLP baseline | — | -1.28 ± 0.544 | -1.36 ± 0.515 | -1.07 ± 0.602 |
| Day 5 change from OLP baseline | — | -1.08 ± 0.552 | -1.35 ± 0.601 | -0.64 ± 0.594 |
| Day 8 change from OLP baseline | — | -0.87 ± 0.578 | -1.28 ± 0.634 | -0.34 ± 0.661 |
| Day 12 change from OLP baseline | — | -0.79 ± 0.603 | -1.21 ± 0.671 | -0.28 ± 0.602 |
| Day 15 change from OLP baseline | — | -0.77 ± 0.604 | -1.23 ± 0.643 | -0.40 ± 0.550 |
| Day 19 change from OLP baseline | — | -0.74 ± 0.639 | -1.20 ± 0.672 | -0.30 ± 0.533 |
| Day 22 change from OLP baseline | — | -0.84 ± 0.597 | -1.15 ± 0.730 | -0.38 ± 0.571 |
| Day 26 change from OLP baseline | — | -0.79 ± 0.687 | -1.21 ± 0.762 | -0.28 ± 0.563 |
| Day 29 change from OLP baseline | — | -0.82 ± 0.604 | -1.24 ± 0.734 | -0.27 ± 0.515 |
| EOS change from OLP baseline | — | -0.39 ± 0.649 | -0.50 ± 0.725 | -0.36 ± 0.702 |
The mean percentage change in S-K levels evaluated relative to both baselines. The results in the table below are presented for RTP.
| Percentage change | Sodium Zirconium Cyclosilicate (ZS) 10g Tid | Sodium Zirconium Cyclosilicate (ZS) 5g | Sodium Zirconium Cyclosilicate (ZS) 10g | Placebo |
|---|---|---|---|---|
| Day 2 percentage change from RTP baseline | — | 1.00 ± 8.459 | -1.74 ± 7.981 | 4.19 ± 10.592 |
| Day 5 percentage change from RTP baseline | — | 5.51 ± 11.337 | -1.52 ± 9.691 | 14.19 ± 13.162 |
| Day 8 percentage change from RTP baseline | — | 10.26 ± 11.340 | 0.16 ± 11.062 | 21.55 ± 15.634 |
| Day 12 percentage change from RTP baseline | — | 12.41 ± 13.113 | 1.60 ± 13.205 | 22.87 ± 16.457 |
| Day 15 percentage change from RTP baseline | — | 12.50 ± 13.378 | 1.27 ± 12.937 | 20.15 ± 14.647 |
| Day 19 percentage change from RTP baseline | — | 13.12 ± 13.180 | 1.70 ± 13.139 | 22.77 ± 14.583 |
| Day 22 percentage change from RTP baseline | — | 11.04 ± 12.993 | 2.66 ± 14.042 | 22.28 ± 18.131 |
| Day 26 percentage change from RTP baseline | — | 12.02 ± 13.616 | 1.49 ± 14.441 | 23.63 ± 15.353 |
| Day 29 percentage change from RTP baseline | — | 11.34 ± 13.821 | 0.87 ± 15.084 | 23.99 ± 15.329 |
| EOS percentage change from RTP baseline | — | 21.62 ± 16.027 | 17.76 ± 16.266 | 20.70 ± 17.035 |
| Day 2 percentage change from OLP baseline | — | -22.12 ± 8.679 | -23.55 ± 7.652 | -18.51 ± 9.751 |
| Day 5 percentage change from OLP baseline | — | -18.77 ± 9.347 | -23.31 ± 9.230 | -10.96 ± 9.724 |
| Day 8 percentage change from OLP baseline | — | -15.01 ± 9.627 | -22.01 ± 10.037 | -5.41 ± 11.424 |
| Day 12 percentage change from OLP baseline | — | -13.55 ± 9.891 | -20.84 ± 10.981 | -4.57 ± 10.335 |
| Day 15 percentage change from OLP baseline | — | -13.35 ± 10.170 | -21.18 ± 10.351 | -6.63 ± 9.457 |
| Day 19 percentage change from OLP baseline | — | -12.79 ± 11.339 | -20.67 ± 10.834 | -4.89 ± 9.279 |
| Day 22 percentage change from OLP baseline | — | -14.49 ± 10.158 | -19.67 ± 11.723 | -6.43 ± 9.759 |
| Day 26 percentage change from OLP baseline | — | -13.35 ± 11.599 | -20.75 ± 12.360 | -4.74 ± 9.551 |
| Day 29 percentage change from OLP baseline | — | -14.09 ± 9.949 | -21.42 ± 11.659 | -4.61 ± 8.802 |
| EOS percentage change from OLP baseline | — | -6.57 ± 11.199 | -8.54 ± 12.405 | -5.95 ± 11.927 |
The results represent number of hyperkalemic patients during the 28-day randomized treatment study phase. The results in the table below are presented for RTP.
| Participants | Sodium Zirconium Cyclosilicate (ZS) 10g Tid | Sodium Zirconium Cyclosilicate (ZS) 5g | Sodium Zirconium Cyclosilicate (ZS) 10g | Placebo |
|---|---|---|---|---|
| Number of Hyperkalemic Patients | — | 66 | 45 | 47 |
The mean changes from OLP baseline in S-Aldosterone and P-Renin levels. The results in the table below are presented for RTP.
| pmol/L | Sodium Zirconium Cyclosilicate (ZS) 10g Tid | Sodium Zirconium Cyclosilicate (ZS) 5g | Sodium Zirconium Cyclosilicate (ZS) 10g | Placebo |
|---|---|---|---|---|
| Day 1 S-Aldosterone | — | -112.69 ± 178.358 | -85.63 ± 118.017 | -98.54 ± 168.657 |
| Day 15 S-Aldosterone | — | -91.75 ± 179.791 | -96.37 ± 108.002 | 39.78 ± 152.050 |
| Day 29 S-Aldosterone | — | -102.70 ± 212.187 | -90.22 ± 91.149 | 41.07 ± 198.266 |
| Day 1 P-Renin | — | -0.23 ± 1.158 | -0.26 ± 1.913 | -0.30 ± 1.031 |
| Day 15 P-Renin | — | -0.39 ± 1.350 | -1.09 ± 4.732 | 0.60 ± 3.250 |
| Day 29 P-Renin | — | -0.27 ± 1.008 | -1.56 ± 4.165 | -0.25 ± 2.725 |
Evaluate health state of patients using EQ-5D questionnaire. This scale is numbered from 0 to 100. 0 means the worst health you can imagine. 100 means the best health you can imagine. The results in the table below are presented for RTP.
| Units on a scale | Sodium Zirconium Cyclosilicate (ZS) 10g Tid | Sodium Zirconium Cyclosilicate (ZS) 5g | Sodium Zirconium Cyclosilicate (ZS) 10g | Placebo |
|---|---|---|---|---|
| OLP baseline | — | 75.0 ± 16.44 | 74.3 ± 17.44 | 72.7 ± 17.32 |
| Day 29 | — | 77.6 ± 16.50 | 76.9 ± 16.08 | 76.6 ± 14.08 |
Collected over Through 28-day randomized treatment study phase day 8-29. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Sodium Zirconium Cyclosilicate (ZS) 10g Tid | 0/267 (0%) | 0/267 (0%) | 0/267 (0%) |
| Sodium Zirconium Cyclosilicate (ZS) 5g | 0/99 (0%) | 4/99 (4%) | 6/99 (6.1%) |
| Sodium Zirconium Cyclosilicate (ZS) 10g | 0/99 (0%) | 3/99 (3%) | 21/99 (21.2%) |
| Placebo | 0/50 (0%) | 1/50 (2%) | 0/50 (0%) |
| Event | Sodium Zirconium Cyclosilicate (ZS) 10g Tid | Sodium Zirconium Cyclosilicate (ZS) 5g | Sodium Zirconium Cyclosilicate (ZS) 10g | Placebo |
|---|---|---|---|---|
| Ankle fractureInjury, poisoning and procedural complications | 0/267 | 0/99 | 0/99 | 1/50 |
| CystitisInfections and infestations | 0/267 | 0/99 | 1/99 | 0/50 |
| Infectious colitisInfections and infestations | 0/267 | 1/99 | 0/99 | 0/50 |
| PneumoniaInfections and infestations | 0/267 | 1/99 | 0/99 | 0/50 |
| Upper respiratory tract infectionInfections and infestations | 0/267 | 0/99 | 1/99 | 0/50 |
| Cardiac failureCardiac disorders | 0/267 | 0/99 | 1/99 | 0/50 |
| Cardiac failure congestiveCardiac disorders | 0/267 | 1/99 | 0/99 | 0/50 |
| HypertensionVascular disorders | 0/267 | 1/99 | 0/99 | 0/50 |
| GastritisGastrointestinal disorders | 0/267 | 1/99 | 0/99 | 0/50 |
| Renal impairmentRenal and urinary disorders | 0/267 | 0/99 | 1/99 | 0/50 |
| Event | Sodium Zirconium Cyclosilicate (ZS) 10g Tid | Sodium Zirconium Cyclosilicate (ZS) 5g | Sodium Zirconium Cyclosilicate (ZS) 10g | Placebo |
|---|---|---|---|---|
| ConstipationGastrointestinal disorders | 0/267 | 1/99 | 9/99 | 0/50 |
| OedemaGeneral disorders | 0/267 | 1/99 | 8/99 | 0/50 |
| Oedema peripheralGeneral disorders | 0/267 | 4/99 | 7/99 | 0/50 |
In RTP there were no subjects analyzed in Sodium Zirconium Cyclosilicate (ZS) 10g tid arm. In OLP, only ZS 10 g TID arm was present. All subjects in RTP took part in OLP.
| Age, Continuous(Years) | Sodium Zirconium Cyclosilicate (ZS) 10g Tid | Sodium Zirconium Cyclosilicate (ZS) 5g | Sodium Zirconium Cyclosilicate (ZS) 10g | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 67.8 ± 10.80 | 66.7 ± 11.40 | 68.0 ± 10.18 | 69.4 ± 10.26 | 67.7 ± 10.70 |
| Sex: Female, Male(Participants) | Sodium Zirconium Cyclosilicate (ZS) 10g Tid | Sodium Zirconium Cyclosilicate (ZS) 5g | Sodium Zirconium Cyclosilicate (ZS) 10g | Placebo | Total |
|---|---|---|---|---|---|
| Female | 96 | 36 | 38 | 14 | 184 |
| Male | 171 | 63 | 61 | 36 | 331 |
| Ethnicity (NIH/OMB)(Participants) | Sodium Zirconium Cyclosilicate (ZS) 10g Tid | Sodium Zirconium Cyclosilicate (ZS) 5g | Sodium Zirconium Cyclosilicate (ZS) 10g | Placebo | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 2 | 0 | 1 | 1 | 4 |
| Not Hispanic or Latino | 265 | 99 | 98 | 49 | 511 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Sodium Zirconium Cyclosilicate (ZS) 10g Tid | Sodium Zirconium Cyclosilicate (ZS) 5g | Sodium Zirconium Cyclosilicate (ZS) 10g | Placebo | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 227 | 87 | 86 | 43 | 443 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 |
| White | 40 | 12 | 13 | 7 | 72 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Country(Participants) | Sodium Zirconium Cyclosilicate (ZS) 10g Tid | Sodium Zirconium Cyclosilicate (ZS) 5g | Sodium Zirconium Cyclosilicate (ZS) 10g | Placebo | Total |
|---|---|---|---|---|---|
| Japan | 68 | 26 | 27 | 13 | 134 |
| Korea | 121 | 46 | 45 | 23 | 235 |
| Russia | 40 | 12 | 13 | 7 | 72 |
| Taiwan | 38 | 15 | 14 | 7 | 74 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Mar 2017 to primary completion in Feb 2018, 11 months.
Results were first posted in Aug 2020, 2 years 6 months after primary completion.
Of 18 phase 3 interventional studies under Hyperkalemia, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 29. This study's 11 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sodium zirconium cyclosilicate